Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Barclays Downgrades Whitbread To Equal Weight

Fri, 04th Dec 2015 09:33

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
BARCLAYS CUTS WHITBREAD TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 5200 PENCE
----------
DEUTSCHE BANK RAISES MEGGITT PRICE TARGET TO 400 (375) PENCE - 'HOLD'
----------
DEUTSCHE BANK RAISES BAE SYSTEMS PRICE TARGET TO 505 (485) PENCE - 'HOLD'
----------
CITIGROUP CUTS INMARSAT TO 'NEUTRAL' ('BUY') - TARGET 1150 PENCE
----------
JPMORGAN RAISES SAGE GROUP TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 670 (500) PENCE
----------
FTSE 250
----------
Cantor Ups JD Sports Fashion Target To 1,200p From 980p, Keeps Buy
----------
Investec Ups JD Sports Fashion Target To 1,100p From 1,040p, Keeps Buy
----------
LIBERUM RAISES BREWIN DOLPHIN HLDGS PRICE TARGET TO 337 (285) PENCE - 'BUY'
----------
Liberum Upgrades John Wood Group To Hold From Sell, Target At 542p
----------
Liberum Upgrades Petrofac To Buy From Hold, Target At 1,302p
----------
Liberum Upgrades Hunting To Hold From Sell, Target At 311p
----------
Liberum Upgrades AMEC Foster Wheeler To Hold From Sell, Target At 476p
----------
HSBC CUTS LANCASHIRE HLDGS TO 'HOLD' ('BUY') - TARGET 680 (715) PENCE
----------
JEFFERIES RAISES TATE & LYLE PRICE TARGET TO 680 (660) PENCE - 'BUY'
----------
JEFFERIES RAISES GREENE KING PRICE TARGET TO 940 (840) PENCE - 'HOLD'
----------
SOCGEN RAISES ICAP PRICE TARGET TO 530 (505) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS COBHAM TO 'SELL' ('HOLD') - TARGET 265 PENCE
----------
UBS RAISES BEAZLEY PRICE TARGET TO 376 (326) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES THOMAS COOK PRICE TARGET TO 104 (100) PENCE - 'SELL'
----------
JPMORGAN RAISES GREENE KING PRICE TARGET TO 1050 (950) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES HALMA PRICE TARGET TO 700 (615) PENCE - 'UNDERWEIGHT'
----------
JPMORGAN RAISES DS SMITH PRICE TARGET TO 460 (440) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES SPIRAX-SARCO PRICE TARGET TO 3250 (3150) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS BODYCOTE PRICE TARGET TO 500 (520) PENCE - 'UNDERWEIGHT'
----------
MAIN MARKET AND AIM
----------
JPMORGAN CUTS FENNER PRICE TARGET TO 140 (150) PENCE - 'UNDERWEIGHT'
----------
Invectec Lifts Ryanair Holdings Target To EUR17.00 From EUR16.00, Keeps Buy
----------
Panmure Gordon Cuts Escher Group Target To 367p From 479p
----------
PANMURE CUTS MIDATECH PHARMA PRICE TARGET TO 417 (420) PENCE - 'BUY'
----------
N+1 Singer Cuts Iomart Group To Hold From Buy, Target At 297p
----------
Liberum Upgrades Lamprell To Buy From Hold, Target At 170p
----------
JEFFERIES RAISES ASOS PRICE TARGET TO 3600 (3500) PENCE - 'HOLD'
----------
GOLDMAN CUTS GENEL ENERGY TO 'NEUTRAL' ('BUY') - TARGET 333 (677) PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2020 16:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jan 2020 15:51

Midatech shares surge on success of latest MTD201 study

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

Read more
8 Jan 2020 09:51

Positive Headline Reading For Latest Midatech MTD201 Study

Positive Headline Reading For Latest Midatech MTD201 Study

Read more
17 Dec 2019 16:39

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Read more
5 Dec 2019 15:59

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Read more
4 Nov 2019 18:47

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Read more
24 Oct 2019 11:50

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Read more
23 Oct 2019 09:29

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Read more
8 Oct 2019 11:34

Midatech Doses First Patients In MTD201 Administration Method Study

Midatech Doses First Patients In MTD201 Administration Method Study

Read more
8 Oct 2019 09:24

Midatech Pharma doses first volunteers in acromegaly treatment study

(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.

Read more
7 Oct 2019 15:45

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

Read more
3 Oct 2019 15:40

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

Read more
30 Sep 2019 19:06

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Read more
24 Sep 2019 14:32

Midatech Pharma Applies To US Regulator For Share Issue Authority

Midatech Pharma Applies To US Regulator For Share Issue Authority

Read more
20 Sep 2019 15:43

Midatech Pharma gets approval for next MTD201 study

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.